Feature | March 24, 2014

New Treatment for Atrial Fibrillation Reduces Stroke Risk

Lariat device seals the left atrial appendage

atrial fibrillation, LARIAT
March 24, 2014 – Doctors at the Stony Brook Heart Institute Electrophysiology Lab are using a new nonsurgical technique called the Lariat Suture Delivery Device to treat patients with atrial fibrillation (AF) who cannot tolerate blood-thinning medication.
 
AF is the most common heart rhythm disorder that causes the upper chambers of the heart to beat fast and erratically. An estimated 2.7 million Americans are living with the disorder, and if uncontrolled, it can have serious consequences, including stroke and early death. Currently, the condition accounts for more than 20 percent of stroke-related deaths.
 
Patients are normally given blood thinners such as warfarin and other anticoagulants to manage their condition by preventing blood clots. However, patients must rigorously manage the level of the drugs in their blood. For most patients, these blood thinners are very effective in reducing the risk of stroke, but there is a potential for bleeding, which in some cases can be serious. For those individuals who cannot tolerate blood thinners due to prior bleeding or who are at a high risk for bleeding, the Lariat procedure can safely reduce the risk of stroke without any further bleeding risk.
 
The Lariat procedure is a nonsurgical, minimally-invasive technique that uses sutures to tie off the left atrial appendage (LAA) of the heart. This area of the heart is the primary source of blood clots leading to stroke in patients with atrial fibrillation.
 
With the patient under general anesthesia, physicians guide two catheters into the patient’s heart to seal the LAA with a pre-tied suture loop — similar to a lasso — with the Lariat device. Rather than a surgical procedure, the technique uses a needle to introduce catheters into the heart.
 
“In the past there weren’t any alternatives that we could really offer these types of patients,” said Roger Fan, M.D., associate professor, department of medicine, director of arrhythmia consult service. “The Lariat is a great alternative to the possibility of a lifetime of blood thinners, which can have some serious side effects like GI bleeds, as well as an alternative to invasive open-heart surgery.” 
 
On Dec. 3, 2013, Fan and his team at the Stony Brook Heart Institute completed their first Lariat procedure without having to spread the ribcage or cut through bone to reach the heart.
 
For more information, visit www.heart.stonybrookmedicine.edu

Related Content

Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Medtronic Announces First Enrollments in STOP AF First Clinical Trial
News | Ablation Systems| July 24, 2017
Medtronic plc recently announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the...
Medtronic Reactive ATP Therapy Slows Progression of Atrial Fibrillation in Real-World Population
News | Atrial Fibrillation| July 03, 2017
Medtronic recently announced that its Reactive ATP therapy slows the progression of atrial fibrillation (AF) in...
Stroke History Higher in Asymptomatic Versus Symptomatic Atrial Fibrillation Patients
News | Stroke| June 28, 2017
Newly diagnosed asymptomatic atrial fibrillation patients have a higher rate of previous stroke than those with...
Biosense webster multielectrode balloon RF ablation catheter

The Biosense Webster multi-electrode balloon RF ablation catheter. Each electrode can have varied power settings to avoid damage to underlying tissues like the esophagus. 

Feature | EP Lab| June 22, 2017 | Dave Fornell
Electrophysiology (EP) technology has been advancing rapidly the past few years with new ablation tools to improve...
Data was positive from the Watchman Left Atrial Appendage Closure (LAAC) Device from the EWOLUTION registry
News | Atrial Fibrillation| May 30, 2017
May 30, 2017 — Data was positive for safety and efficacy rates of the Watchman Left Atrial Appendage Closure (LAAC) D
Abbott SJM Confirm RX Implantable cardiac monitor gains european CE mark approval
News | May 30, 2017
May 30, 2017 — Abbott recently announced European CE mark and first use of the new Confirm Rx Insertable Cardiac Moni
Overlay Init